|
2
|
12
|
4xssF |
Insulin-like growth factor i in complex with site 1 of a hybrid insulin receptor / type 1 insulin-like growth factor receptor |
|
96
|
326
|
4wrgA |
1.9 angstrom structure of egfr kinase domain |
|
91
|
327
|
4wkqA |
1.85 angstrom structure of egfr kinase domain with gefitinib |
|
89
|
302
|
4uwbA |
Fibroblast growth factor receptor 1 kinase in complex with jk-p5 |
|
50
|
277
|
4wrlA |
Structure of the human csf-1:csf-1r complex |
|
91
|
301
|
4uwyA |
Fgfr1 apo structure |
|
79
|
328
|
4wd5A |
Crystal structure of egfr 696-1022 t790m in complex with ql-x138 |
|
91
|
296
|
4uxlA |
Structure of human ros1 kinase domain in complex with pf-06463922 |
|
79
|
280
|
4x3jA |
Selection of fragments for kinase inhibitor design: decoration is key |
|
90
|
301
|
4uwcA |
Fibroblast growth factor receptor 1 kinase in complex with jk-p3 |
|
33
|
176
|
4w4zA |
Structure of the epha4 lbd in complex with peptide |
|
83
|
299
|
4uxqA |
Fgfr4 in complex with ponatinib |
|
17
|
98
|
4wv1C |
Crystal structure of the fgfr2 d2 domain in complex with fab 2b.1.3 |
|
78
|
480
|
4ux8A |
Ret recognition of gdnf-gfralpha1 ligand by a composite binding site promotes membrane-proximal self-association |
|
31
|
177
|
4w50A |
Structure of the epha4 lbd in complex with peptide |
|
89
|
301
|
4wunA |
Structure of fgfr1 in complex with azd4547 (n-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-5-yl}-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide) at 1.65 angstrom |
|
144
|
612
|
4uipA |
The complex structure of extracellular domain of egfr with repebody (rac1). |
|
76
|
479
|
4wrmA |
Structure of the human csf-1:csf-1r complex |
|
156
|
613
|
4uv7A |
The complex structure of extracellular domain of egfr and gc1118a |
|
104
|
307
|
4tt7A |
Crystal structure of human alk with a covalent modification |
|
90
|
305
|
4rwiA |
Crystal structure of v561m fgfr1 gatekeeper mutation (c488a, c584s, v561m), apo |
|
74
|
303
|
4tyeA |
Structural analysis of the human fibroblast growth factor receptor 4 kinase |
|
87
|
301
|
4rwlA |
Crystal structure of fgfr1 (c488a, c584c) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide (e3810) |
|
82
|
310
|
4tyjA |
Structural analysis of the human fibroblast growth factor receptor 4 kinase |
|
96
|
297
|
4twnA |
Human epha3 kinase domain in complex with birb796 |
|
90
|
308
|
4rwjA |
Crystal structure of fgfr1 (c488a, c584s) in complex with azd4547 (n-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-5-yl}-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide) |
|
67
|
305
|
4tyiA |
Structural analysis of the human fibroblast growth factor receptor 4 |
|
86
|
323
|
4tksA |
Native-sad phasing for human egfr kinase domain. |
|
84
|
308
|
4tygA |
Structural analysis of the human fibroblast growth factor receptor 4 kinase |
|
91
|
298
|
4twoA |
Human epha3 kinase domain in complex with compound 164 |
|
78
|
277
|
4trlA |
Structure of ephrin type-a receptor 2 |
|
82
|
308
|
4rwkA |
Crystal structure of v561m fgfr1 gatekeeper mutation (c488a, c584s, v561m) in complex with n-{3-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-5-yl}-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide (azd4547) |
|
100
|
311
|
4u0iA |
Crystal structure of kit in complex with ponatinib |
|
90
|
352
|
4rt7A |
Crystal structure of flt3 with a small molecule inhibitor |
|
90
|
297
|
4qrcA |
Crystal structure of the tyrosine kinase domain of fgf receptor 4 in complex with ponatinib |
|
71
|
281
|
4rixA |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-q790r mutation |
|
91
|
322
|
4rj6A |
Egfr kinase (t790m/l858r) with inhibitor compound 4 |
|
69
|
281
|
4riyA |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-e909g mutation |
|
70
|
281
|
4riwA |
Crystal structure of an egfr/her3 kinase domain heterodimer |
|
88
|
323
|
4rj5A |
Egfr kinase (t790m/l858r) with inhibitor compound 5 |
|
83
|
309
|
4qq5A |
Crystal structure of fgf receptor (fgfr) 4 kinase harboring the v550l gate-keeper mutation in complex with fiin-2, an irreversible tyrosine kinase inhibitor capable of overcoming fgfr kinase gate-keeper mutations |
|
77
|
297
|
4rixB |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-q790r mutation |
|
95
|
302
|
4r7iA |
Crystal structure of fms kinase domain with a small molecular inhibitor, gleevec |
|
88
|
308
|
4qqcA |
Crystal structure of fgf receptor (fgfr) 4 kinase domain in complex with fiin-2, an irreversible tyrosine kinase inhibitor capable of overcoming fgfr kinase gate-keeper mutations |
|
94
|
322
|
4rj8A |
Egfr kinase (t790m/l858r) with inhibitor compound 8 |
|
91
|
322
|
4rj4A |
Egfr kinase (t790m/l858r) with inhibitor compound 6 |
|
100
|
326
|
4r7hA |
Crystal structure of fms kinase domain with a small molecular inhibitor, plx3397 |
|
76
|
297
|
4riyB |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-e909g mutation |
|
33
|
191
|
4ra0C |
An engineered axl 'decoy receptor' effectively silences the gas6-axl signaling axis |
|
95
|
291
|
4r1vA |
Identification and optimization of pyridazinones as potent and selective c-met kinase inhibitors |
